Patient insights data

While there are many sources of real-world evidence, there’s growing interest and focus on capturing patient generated insights to capture a more specific level of understanding for a given therapy.

Oct. 10, 2022

The evolving roles and responsibilities of digital opinion leaders in medical education

In the past, patients entrusted their healthcare providers to provide information about health-related matters.

Oct. 3, 2022

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Compass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success

The company's CEO, Kabir Nath, discusses potential roadblocks to commecialization that await its psilocybin treatment for depression. 

By Meagan Parrish • Sept. 27, 2022

Why precision medicine could be the next frontier in treating autism

Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.

By Kelly Bilodeau • Sept. 27, 2022

That’s not Angry Birds — that’s your doctor learning about novel drugs through gaming

How pharma companies can teach physicians about mechanism of action and other medication lessons with interactive mobile games.

By Alexandra Pecci • Sept. 26, 2022

Methadone at home? Emerging tech provides new tool in the fight against opioid addiction

Sonara Health’s inexpensive, specially engineered label and web app allow for at-home, digitally supervised dosing of high-cost or high-risks drugs.

By Alexandra Pecci • Sept. 15, 2022

Medication affordability’s impact on adherence and outcomes

Improved patient affordability is an important lever that can increase adherence, which in turn can improve health outcomes.

Sept. 12, 2022

Pharma’s renewed sickle cell investment lifts a once-shirked disease

Pfizer's $5.4 billion deal to acquire Global Blood Therapeutics invigorated the fast-growing market, and patients are fit to be the benefactors.

By Kelly Bilodeau • Sept. 1, 2022

Flipping the script to disrupt, redefine and accelerate the patient care journey

A new, digitally innovative care model empowers patients and expedites their access to treatment.

Aug. 22, 2022

3 ways pharma can prep for Biden’s sweeping drug pricing policies

Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.

By Karissa Waddick • Aug. 18, 2022

The CEO in the ophthalmologist’s coat

In balancing two roles — Lexitas CEO and practicing physician — George Magrath brings a patient-first perspective to developing and advancing eye treatments.

By Alexandra Pecci • Aug. 16, 2022

Right under our noses: Could COVID-19 vaccines be better as nasal spray?

Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.

By Kelly Bilodeau • Aug. 16, 2022

Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics

Galderma may not have the biggest name in aesthetics, but as the sector grows past pandemic lows, the company is relying on its people to build a loyal customer base.

By Michael Gibney • Aug. 11, 2022

4 ways to nail the launch of your cell therapy

A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.

By Meagan Parrish • Aug. 10, 2022

The ‘alarming’ spread of Monkeypox — by the numbers

With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’

By Meagan Parrish • Aug. 8, 2022

Generic subscription services like Mark Cuban’s promise cheaper drugs — but will it work?

Companies like Cost Plus Drugs and DiRx can bring generics directly to consumers at a fraction of the price, but whether it’s enough to fix the inflated U.S. healthcare system is yet to be seen.

By Michael Gibney • Aug. 4, 2022

Lupus discovery lends clues to the fight against long COVID

So far, pharma has yet to provide an answer for long COVID. But award-winning lupus research by Yale professor Akiko Iwasaki could help lead the way.

By Kelly Bilodeau • July 27, 2022

Democrats think they've found a balance between drug innovation and pricing negotiation

A look at Congress’ push to pass drug pricing reform and why the latest attempt could actually succeed.

By Karissa Waddick • July 26, 2022

Behind Pfizer's new quest to target a 'transformation' in pharma

A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.

By Kelly Bilodeau • July 25, 2022

The earlier the better: New consortium leverages infant screening to accelerate treatment

Inozyme Pharma has joined a genomic sequencing program developing a novel rapid test for 388 genetic diseases.

By Kim Ribbink • July 25, 2022

Moderna's next vax target? A little-known cause of birth defects

How the mRNA-based biotech is developing the first-ever prophylactic for a devastating virus.

By Karissa Waddick • July 21, 2022

Pfizer's former R&D head takes on drug pricing misconceptions in new book

John LaMattina has something to say about the industry — and he hopes patients are listening.

By Meagan Parrish • July 19, 2022

How digital health is changing the relationship between patients and health providers

The pandemic has forced the pharmaceutical industry to look at digital in a new way - and it’s driving better health outcomes

July 18, 2022

The power of the underdog: A rare disease nonprofit working to help patients win against the odds

Elizabeth Izard Apelles is finding innovative ways to champion rare disease patients through an emerging platform from Honeycomb Health.

By Alexandra Pecci • July 13, 2022

Pharma companies take a fresh approach to inclusion in new DTC ads

AstraZeneca and Amgen are emphasizing diversity and authenticity in campaigns for lupus and severe asthma therapies.

By Karissa Waddick • July 5, 2022